ABPI Proposes ‘World-First’ Investment Facility As Part Of New Pricing Deal
A ‘Medicines Equity Partnership’ Is Also On The Cards
The Association of the British Pharmaceutical Industry says a new type of investment facility funded by the pharmaceutical industry could form part of a new pricing agreement for branded medicines, and would be a “genuine Brexit dividend.”
You may also be interested in...
A new report accuses big pharma of excessive pricing and costing the National Health Service billions of pounds. The Association of the British Pharmaceutical Industry has refuted the claims.
The UK pharmaceutical industry association, the ABPI, says it and the government are still far from reaching a deal on a new voluntary pricing agreement and has suggested that a transition to the statutory scheme could be on the cards if an acceptable deal cannot be secured.
Susan Rienow, UK country president of Pfizer, is to formally replace Pinder Sahota, UK manager of Novo Nordisk, as president of the UK pharmaceutical industry trade group, the ABPI.